ABSTRACT
In the pharmaceutical industry, improving the early detection of drug-induced hepatotoxicity is essential as it is one of the most important reasons for attrition of candidate drugs during the later stages of drug development. The first objective of this study was to better characterize different cellular models (i.e., HepG2, HepaRG cells, and fresh primary human hepatocytes) at the gene expression level and analyze their metabolic cytochrome P450 capabilities. The cellular models were exposed to three different CYP450 inducers; beta-naphthoflavone (BNF), phenobarbital (PB), and rifampicin (RIF). HepG2 cells responded very weakly to the different inducers at the gene expression level, and this translated generally into low CYP450 activities in the induced cells compared with the control cells. On the contrary, HepaRG cells and the three human donors were inducible after exposure to BNF, PB, and RIF according to gene expression responses and CYP450 activities. Consequently, HepaRG cells could be used in screening as a substitute and/or in complement to primary hepatocytes for CYP induction studies. The second objective was to investigate the predictivity of the different cellular models to detect hepatotoxins (16 hepatotoxic and 5 nonhepatotoxic compounds). Specificity was 100% with the different cellular models tested. Cryopreserved human hepatocytes gave the highest sensitivity, ranging from 31% to 44% (depending on the donor), followed by lower sensitivity (13%) for HepaRG and HepG2 cells (6.3%). Overall, none of the models under study gave desirable sensitivities (80-100%). Consequently, a high metabolic capacity and CYP inducibility in cell lines does not necessarily correlate with a high sensitivity for the detection of hepatotoxic drugs. Further investigations are necessary to compare different cellular models and determine those that are best suited for the detection of hepatotoxic compounds.
Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Cytochrome P-450 Enzyme System/metabolism , Drug-Related Side Effects and Adverse Reactions , Hepatocytes/drug effects , RNA, Messenger/genetics , Toxicity Tests/methods , Adult , Aged , Chemical and Drug Induced Liver Injury/enzymology , Chemical and Drug Induced Liver Injury/genetics , Child , Cytochrome P-450 Enzyme System/biosynthesis , Enzyme Induction , Female , Gene Expression/drug effects , Gene Expression Profiling , Hep G2 Cells , Hepatocytes/enzymology , Hepatocytes/metabolism , Humans , Inhibitory Concentration 50 , Lethal Dose 50 , Male , Middle Aged , Models, Biological , Predictive Value of Tests , Principal Component Analysis , ToxicogeneticsABSTRACT
Levetiracetam and its carboxylic metabolite (AcL) were tested for their potential inhibitory effect on 11 different drug metabolizing enzyme activities using human liver microsomes. The following specific assays were investigated: testosterone 6beta-hydroxylation [cytochrome P-450 3A4 (CYP3A4)], coumarin hydroxylation (CYP2A6), (R)-warfarin hydroxylation (CYP1A2), (S)-mephenytoin hydroxylation (CYP2C19), p-nitrophenol hydroxylation (CYP2E1) tolbutamide hydroxylation (CYP2C9), dextromethorphan O-demethylation (CYP2D6), epoxide hydrolase and UDP-glucuronyltransferase (UGT) toward paracetamol (UGT1*6), ethinyloestradiol (UGT1*1), p-nitrophenol (UGT(pl 6.2)), and valproic acid. None of these activities were affected by levetiracetam or AcL added at concentrations up to 1 mM. Additionally, primary cultures of rat hepatocytes were used to assess a potential inducing effect of levetiracetam on CYPs. Phenobarbital (2 mM), beta-naphtoflavone (40 microM), dexamethasone (1 microM), and phenytoin (up to 300 microM) were tested as positive controls. When added to cells for 48 h, all the positive controls increased 7-ethoxycoumarin O-deethylase activity demonstrating the inducibility of CYPs in the present culture conditions. By contrast, levetiracetam did not affect the activity up to 1 mM. The highest levetiracetam concentrations examined in the above in vitro studies are well in excess of those measured in the plasma of patients receiving therapeutic doses. It is thus concluded that levetiracetam is unlikely to produce pharmacokinetic interactions through inhibition of CYPs, UGTs, and epoxide hydrolase. Furthermore, based on the in vitro assays with rat hepatocytes, it could be speculated that levetiracetam does not act as a CYP inducer.
Subject(s)
Anticonvulsants/pharmacology , Piracetam/analogs & derivatives , Animals , Anticonvulsants/metabolism , Biomarkers , Butyrates/pharmacology , Cytochrome P-450 Enzyme Inhibitors , Drug Interactions , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Epoxide Hydrolases/antagonists & inhibitors , Glucuronosyltransferase/antagonists & inhibitors , Humans , In Vitro Techniques , Levetiracetam , Liver/cytology , Liver/drug effects , Liver/metabolism , Male , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Piracetam/metabolism , Piracetam/pharmacology , Pyrrolidinones/pharmacology , Rats , Rats, Sprague-DawleyABSTRACT
Proliferation, morphology and time course patterns of marker enzyme activities of primary cultures of renal rabbit proximal tubule cells (RPT cells) and Opossum kidney cells (OK cells) in antibiotic-free and serum-free defined medium were investigated. Both RPT and OK cells grew to confluency within 6-8 days. RPT cells were thicker and displayed higher density of both microvilli and mitochondria when compared with OK cells. RPT cells exhibited higher activity of glutathione-S-transferase when compared with OK cells, whereas in the latter, higher glutathione content could be detected. Apical and basolateral membrane enzymes were higher in RPT cells than in OK cells. Stable high glycolytic activity and low gluconeogenesis activity in OK cells pointed out a strict dependence on glycolysis, whereas RPT cells exhibited glucose metabolism shift towards the glycolysis pathway.
